NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share their insights.
- Other contributors include Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and Naval G. Daver, MD.
- Additional experts such as Jessica Altman, MD, and Amir T. Roboz, MD, also provide their perspectives.
No direct quotes are available in the provided text.
Author's summary: NGS improves biomarker testing in solid tumors.
More News
- First Duel Night Abyss Figure Is Based on Psyche
- Praia Health’s Kurt Hammond on Powering Providence’s Work With Labcorp
- Second Phase of FIFA 2026 World Cup Tickets Launches
- Importing beef is not the solution | GABEL
- Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age | PharmExec
- 'Harvest Now, Decrypt Later' Attacks Drive Quantum Urgency
- Court: Federal Agencies Broke Laws in Approving Massive Logging Project in Montana Grizzly Country
- Quantum Threats Demand Post-Quantum Cryptography Now
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups